Consequences on neurological development in children with Lennox-Gastaut Syndrome
DOI:
https://doi.org/10.33448/rsd-v13i4.45635Keywords:
Childhood epilepsy; Child; Growth and development; Convulsive crises; Child neurodevelopment.Abstract
Lennox-Gastaut Syndrome (LGS) is a severe epileptic encephalopathy with onset in childhood, which accounts for 4% of childhood epilepsies. GLS does not yet have a defined etiopathogenesis and treatment, resulting in a poor prognosis for these patients. Several treatments are being studied to control convulsive episodes and to neuroprotect these patients. This review aimed to identify what the consequences would be for the neurological development of children with LGS and the treatments available through a systematic bibliographic review, of publications from 2014 to 2024, in Portuguese, English and Spanish. A survey was carried out in the PubMed and SciELO databases. There are few studies on the subject, a reality that needs to be changed so that these infants have a better quality of life. But despite this, it is concluded that although the neuropsychomotor system is still affected even when using the treatment, these children still have an advantage in neurological development when compared to therapy to stop epileptic seizures.
References
Alexander, D., Campos Jr., D. & Lopez, F. A. (2014). Tratado de pediatria. 2. Ed. Manole.
Alsaad, A. M. S., & Koren, G. (2014). Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials. British Journal of Clinical Pharmacology, 78(6), 1264–1271. https://doi.org/10.1111/bcp.12479
Arzimanoglou, A., José Alexandre Ferreira, Satlin, A., Mendes, S., Williams, B., Critchley, D., Schuck, E., Hussein, Z., Kumar, D., Shobha Dhadda, & Bibbiani, F. (2016). Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology, 20(3), 393–402. https://doi.org/10.1016/j.ejpn.2015.12.015
Arzimanoglou, A., José Alexandre Ferreira, Satlin, A., Olhaye, O., Kumar, D., Shobha Dhadda, & Bibbiani, F. (2019). Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303. European Journal of Paediatric Neurology, 23(1), 126–135. https://doi.org/10.1016/j.ejpn.2018.09.010
Brigo, F., Jones, K., Eltze, C., & Matricardi, S. (2021). Anti-seizure medications for Lennox-Gastaut syndrome. Cochrane Database of Systematic Reviews, 2022(9). https://doi.org/10.1002/14651858.cd003277.pub4
Conceicao, H. C. da, Salino, A. V., Queiroz, A. K. de S., Ribeiro, E. de O. A., Soares, K. S., & Prestes, G. B. de R. (2017). Síndrome de Lennox-Gastaut: relato de caso. Archives of health investigation, 6(2). https://doi.org/10.21270/archi.v6i2.1805
Cross, J. H., Auvin, S., Falip, M., Striano, P., & Arzimanoglou, A. (2017). Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations. Frontiers in Neurology, 8. https://doi.org/10.3389/fneur.2017.00505
Dalic, L. J., Aaron, Bulluss, K. J., Thevathasan, W., Roten, A., Leonid Churilov, & Archer, J. S. (2021). DBS of Thalamic Centromedian Nucleus for Lennox–Gastaut Syndrome (ESTEL Trial). Annals of Neurology, 91(2), 253–267. https://doi.org/10.1002/ana.26280
Dibué, M., Greco, T., Spoor, J. K. H., Tahir, Z., Specchio, N., Hänggi, D., Steiger, H., & Kamp, M. A. (2020). Vagus nerve stimulation in patients with Lennox‐Gastaut syndrome: A meta‐analysis. Acta Neurologica Scandinavica, 143(5), 497–508. https://doi.org/10.1111/ane.13375
Hahn, C. D., Jiang, Y., Villanueva, V., Zolnowska, M., Arkilo, D., Hsiao, S., Asgharnejad, M., & Dlugos, D. (2022). A phase 2, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox–Gastaut syndrome (ELEKTRA). Epilepsia, 63(10), 2671–2683. https://doi.org/10.1111/epi.17367
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional. (n.d.). https://doi.org/10.20453/rnp.v81i2.3337
Sampaio, R., & Mancini, M. (2007). Estudos de revisão sistemática: um guia para síntese criteriosa da evidência científica. Revista Brasileira de Fisioterapia, 11(1), 83–89. https://doi.org/10.1590/s1413-35552007000100013
Se Hee Kim, Han Som Choi, Chung Mo Koo, Joo, B.-R., Byung Joo Park, Hae Kook Lee, Joon Soo Lee, Heung Dong Kim, & Hoon Chul Kang. (2022). Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy. The Journal of Clinical Neurology, 18(5), 547–547. https://doi.org/10.3988/jcn.2022.18.5.547
Knupp, K. G., Scheffer, I. E., Ceulemans, B., Sullivan, J. E., Nickels, K. C., Lagae, L., Guerrini, R., Zuberi, S. M., Nabbout, R., Riney, K., Shore, S., Agarwal, A., Lock, M., Farfel, G. M., Galer, B. S., Gammaitoni, A. R., Davis, R., & Gil-Nagel, A. (2022). Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2022.0829
Knupp, K. G., Scheffer, I. E., Berten Ceulemans, Sullivan, J., Nickels, K. C., Lieven Lagae, Guerrini, R., Zuberi, S. M., Nabbout, R., Riney, K., Agarwal, A., Lock, M., Dai, D., Farfel, G., Galer, B. S., Gammaitoni, A. R., Polega, S., Davis, R. L., & António Gil-Nagel. (2022). Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open‐label extension study. Epilepsia, 64(1), 139–151. https://doi.org/10.1111/epi.17431
Kopciuch, D., Fliciński, J., Steinborn, B., Winczewska-Wiktor, A., Paczkowska, A., Zaprutko, T., Ratajczak, P., Nowakowska, E., & Kus, K. (2022). Pharmacoeconomics Aspects of Antiepileptic Drugs in Pediatric Patients with Epilepsy. International Journal of Environmental Research and Public Health, 19(12), 7517. https://doi.org/10.3390/ijerph19127517
Morita, D., A., & Glauser, T., A. (2013). Lennox -Gastaut and related syndromes. Pediatric epilepsy. 213-22.
Ohtsuka, Y., Yoshinaga, H., Shirasaka, Y., Takayama, R., Takano, H., & Iyoda, K. (2014). Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: A randomized double-blind placebo-controlled trial in Japan. Epilepsy Research, 108(9), 1627–1636. https://doi.org/10.1016/j.eplepsyres.2014.08.019
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., & McGuinness, L. A. (2021). PRISMA 2020 Explanation and elaboration: Updated Guidance and Exemplars for Reporting Systematic Reviews. BMJ, 372(160). NCBI. https://doi.org/10.1136/bmj.n160
Panda, P. K., Sharawat, I. K., Dawman, L., Panda, P., Kasinathan, A., & Rathaur, V. K. (2022). Efficacy and Tolerability of Lacosamide in Lennox–Gastaut Syndrome: A Systematic Review and Meta-analysis. Journal of Neurosciences in Rural Practice, 13(01), 032–042. https://doi.org/10.1055/s-0041-1740580
Privitera, M., Bhathal, H., Wong, M., Cross, J. H., Wirrell, E., Marsh, E. D., Mazurkiewicz‐Beldzinska, M., Villanueva, V., Checketts, D., Knappertz, V., & VanLandingham, K. (2021). Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials. Epilepsia, 62(5), 1130–1140. https://doi.org/10.1111/epi.16878
Zhang, L., Wang, J., & Wang, C. (2021). Efficacy and safety of antiseizure medication for Lennox–Gastaut syndrome: a systematic review and network meta‐analysis. Developmental Medicine & Child Neurology, 64(3), 305–313. https://doi.org/10.1111/dmcn.15072
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Maria Eduarda Notaro Cavalcanti; Lavínia Pessoa de Melo Albuquerque Cavalcanti; Letícia Bezerra de Almeida; Maria Júlia Tenório Oliveira da Silva; Roberta Gomes Barros ; Wagner Gonçalves Horta
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
